

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 23521.0159
		U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR -09/623922
INTERNATIONAL APPLICATION NO. PCT/US99/05853	INTERNATIONAL FILING DATE 12 MARCH 1999	PRIORITY DATE CLAIMED 12 MARCH 1998
TITLE OF INVENTION CHOLESTEROL RECOGNITION SEQUENCE		
APPLICANT(S) FOR DO/EO/US VASSILIOS PAPADOPOULOS AND HUA LI		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> has been transmitted by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. A copy of the International Search Report (PCT/ISA/210).8. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> have been transmitted by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).		
Items 13 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none">13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.15. <input checked="" type="checkbox"/> A FIRST preliminary amendment.16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.17. <input type="checkbox"/> A substitute specification.18. <input type="checkbox"/> A change of power of attorney and/or address letter.19. <input type="checkbox"/> Certificate of Mailing by Express Mail20. <input checked="" type="checkbox"/> Other items or information:		
Verified Statement by A Non-Inventor Supporting A Claim by Another for Small Entity Status		

Page 2 of 2

09/623922

533 Rec'd PCT/PTO 11 SEP 2000

23251.0159

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

VASSILIOS PAPADOPOULOS ET AL.

ATTN. APPLICATION BRANCH

Serial No. U.S. Nat'l. Phase of
PCT/US99/05853

Int'l. Filing Date: March 12, 1999

For: CHOLESTEROL RECOGNITION SEQUENCE

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the filing fee, please amend the above-identified application as follows.

IN THE CLAIMS

Please renumber Claim 31 (second occurrence) to Claim 36 as claims 32 - 37.

Claim 33 (as renumbered) line 1, change "31" to - - 32 - -;

Claim 37 (as renumbered) line 1, change "35" to - - 36 - -.

REMARKS

The foregoing amendment is being made to correct the inadvertent erroneous numbering of the claims. The dependencies of claims 33 and 37 have been corrected to be consistent with

[illegible]

VASSILIOS PAPADOPOULOS ET AL.

Robin L. Teskin
Robin L. Teskin
Registration No. 35,030

Document #: 991771 v.1

12/Part

09/623922

533 Rec'd PCT/PTO 11 SEP 2000

TITLE OF THE INVENTION

Cholesterol Recognition Sequence

by

5 Vassili Papadopoulos

Hua Li

INTRODUCTION

10 The primary point of control in the acute
stimulation of steroidogenesis by hormones involves
the first step in this biosynthetic pathway where
cholesterol is converted to pregnenolone by the C₂₇
cholesterol side chain cleavage cytochrome P-450
enzyme (P-450scc) and auxiliary electron transferring
15 proteins, localized on inner mitochondrial membranes
(IMM) (Simpson, E.R. and Waterman, M. R., 1983, *Can.*
J. Biochem. Cell. Biol. 61:692-717; Jefcoate, C. R. et
al. 1992, *J. Steroid Biochem. Molec. Biol.* 43: 751-
767). More detailed studies have shown that the
20 reaction catalyzed by P-450scc is not the rate-
limiting step in the synthesis of steroid hormones.
Rather, the rate-limiting step is the transport of the
precursor, cholesterol, from intracellular sources to
the IMM. This hormone-dependent transport mechanism
25 was shown to be localized in the mitochondrion
(Simpson and Waterman, 1983, *supra*; Jefcoate et al.,
1992, *supra*). All documents cited herein *supra* and
infra are hereby incorporated in their entirety by
reference thereto.

30 The peripheral-type benzodiazepine receptor (PBR)
was originally discovered because it binds the
benzodiazepine diazepam with relatively high affinity
(Papadopoulos, V. 1993, *Endocr. Rev.* 14:222-240).
Benzodiazepines are among the most highly prescribed

drugs due to their pharmacological actions in relieving anxiety mediated through modulating the activity of γ -aminobutyric acid receptors in the central nervous system (Costa, E. and Guidotti, A. 1979, *Annu. Rev. Pharmacol. Toxicol.* 19:531-545). PBR is another class of binding sites for benzodiazepines distinct from the aforementioned neurotransmitter receptors. Further studies demonstrated that in addition to benzodiazepines, PBR binds other classes of organic compounds with high affinity (Papadopoulos, 1993, *supra*). PBR, although present in all tissues examined, was found to be particularly high in steroid producing tissues, where it was primarily localized in the outer mitochondrial membrane (OMM) (Anholt, R.R.H. et al. 1986, *J. Biol. Chem.* 261:576-583). An 18 kDa isoquinoline-binding protein was identified as PBR, cloned and expressed (Papadopoulos, V. 1998, *Proc Soc. Exp. Biol. Med.* 217:130-142). It was then demonstrated that PBR is a functional component of the steroidogenic machinery (Papadopoulos, 1998, *supra*; Papadopoulos V. et al. 1990, *J. Biol. Chem.* 265:3772-3779) mediating cholesterol delivery from the outer to the inner mitochondrial membrane (Krueger, K. E. and Papadopoulos, V. 1990, *J. Biol. Chem.* 265:15015-15022). Further studies demonstrated that pharmacologically induced reduction of adrenal PBR levels *in vivo* resulted in decreased circulating glucocorticoid levels (Papadopoulos, V. 1998, *supra*). In addition, targeted disruption of the PBR gene in Leydig cells resulted in the arrest of cholesterol transport into mitochondria and steroid formation; transfection of the mutant cells with a PBR cDNA rescued steroidogenesis (Papadopoulos, V. et al. 1997, *J. Biol. Chem.* 272:32129-32135). How PBR affected

cholesterol transport and whether or not PBR directly interacted with cholesterol was not known.


SUMMARY OF THE INVENTION

5 Based on the known amino acid sequence of the human and mouse 18 kDa PBR protein, a three dimensional model of this receptor protein was developed using molecular dynamics simulations (Bernassau, J. M. et al. 1993, *J. Mol. Graph.* 11:236-
10 245; Papadopoulos, V. 1996, In: Payne A. H., Hardy, M. P., Russell, L. D. (eds) The Leydig Cell. Cashe River Press, Vienna, IL, pp 598-628). Analysis of the three dimensional structure indicated that both the human and mouse PBR could possibly accomodate cholesterol
15 and function as a channel. In this invention is described the testing and proof of this hypothesis.

 In the present invention, we identify a cholesterol recognition amino acid sequence on PBR, common to all proteins shown to interact with
20 cholesterol, and demonstrate that PBR functions as a cholesterol channel-like structure, mediating cholesterol transport across membranes.

 Cholesterol, coming from various intracellular sources, is recognized by the cholesterol
25 recognition/interaction amino acid consensus pattern present in the carboxy-terminal of PBR in the outer mitochondrial membrane (OMM). This pool of cholesterol enters in the (OMM) at the PBR sites where it remains without mixing with other membrane
30 components. Ligand binding to the receptor induces the release of this cholesterol. When it is released, the cholesterol can be accessed by the P450scc and cleaved into pregnenolone, precursor of all steroids.

Therefore, it is an object of the present invention to provide a consensus sequence for the recognition/interaction of cholesterol comprising



5 wherein Z represents a neutral and hydrophobic amino acid, such as Leucine or Valine, Y represents a neutral and polar amino acid, such as Tyrosine, Q represents a basic amino acid, such as Arginine or Lysine and X represents any amino acid. The presence
10 of the consensus sequence in a protein infers the likelihood of interaction with cholesterol.

It is another object of the present invention to provide a nucleotide sequence encoding the consensus sequence described above, and vectors incorporating
15 all or part of said sequence, and cells, prokaryotic and eukaryotic, transformed or transfected with said vectors, for use in the production of peptides having a cholesterol interaction/recognition sequence. The transformed or transfected cells are useful for
20 screening agents or drugs which alter cholesterol interaction/recognition, and uptake of cholesterol.

It is yet another object of the present invention to provide a method for identifying whether or not a protein recognizes or interacts with cholesterol said
25 method comprising identifying the presence or absence of the above-mentioned cholesterol recognition/interaction consensus sequence wherein the presence of the sequence is an indication of the likelihood that the protein recognizes/interacts with cholesterol.

30 It is yet another object of the present invention to provide a method for conferring to a molecule the ability to interact with cholesterol by introducing into a molecule or polypeptide, natural or synthetic, a cholesterol recognition/interaction sequence such

that the protein or polypeptide, natural or synthetic, is now able to recognize/interact with cholesterol.

It is still another object of the present invention to provide a molecule, natural or synthetic
5 comprising the cholesterol recognition/interaction sequence described above.

It is a further object of the present invention to provide a molecule which blocks or competes with the cholesterol interaction/recognition ability of the
10 cholesterol recognition/interaction consensus sequence described above. The molecule can be an antibody, a peptide, a peptide comprising the cholesterol interaction/recognition consensus sequence, or drug.

It is yet another object of the present invention
15 to provide a method for altering the cholesterol binding ability of molecules which contain the cholesterol recognition/interaction consensus sequence described above, comprising altering said site such that cholesterol recognition is reduced, eliminated or
20 increased. Cholesterol recognition can be increased by providing a perfect cholesterol pocket, or alternatively, by providing more than one consensus sequence in a protein or molecule.

It is further another object of the present
25 invention to provide a PBR with reduced ability to recognize and interact with cholesterol by modifying the cholesterol recognition/interaction site of PBR, for example by changing amino acid 153 from tyrosine to serine, or by changing amino acid 155 from arginine
30 to leucine. These modification or similar modifications may be used for reducing the cholesterol recognition/interaction or binding of other proteins or agents which contain the cholesterol interaction/recognition consensus sequence described
35 above.

It is another object of the present invention to provide a method for increasing the presence of cholesterol inside the cell by introducing a PBR ligand such that the cholesterol is released from PBR.

5 It is another object of the present invention to provide a method for decreasing the presence of cholesterol inside the cell by introducing an agent which inhibits PBR ligand binding to PBR thereby inhibiting the release of cholesterol from PBR. Said
10 agent can be any molecule, peptide, or drug.

It is yet another object of the present invention to provide a method for increasing the presence of cholesterol inside the cell by introducing an agent which results in overexpression of the PBR, or
15 increase in a peptide comprising the cholesterol interaction/recognition sequence, by gene therapy for example, or altering the distribution and compartmentalization of cholesterol by targetting the cholesterol interaction/recognition sequence to a
20 specific organelle in the cell, i.e. by addign a signal sequence specific for nuclear insertion at the N-terminus

It is yet another object of the present invention to provide a method for increasing pregnenolone
25 production in a steroidogenic cell, comprising providing a PBR ligand to said cell such that PBR releases cholesterol which is then available for cleavage into pregnenolone. Alternatively, a peptide comprising the cholesterol interaction/recognition
30 sequence can be provided to a steroidogenic cell, i.e. by gene therapy, thereby increasing the presence of cholesterol in a steroidogenic cell, resulting in an increase of pregnenolone production.

It is another object of the present invention to
35 provide a method for decreasing pregnenolone

production in a steroidogenic cell, comprising
providing a PBR ligand inhibitor to said cell such
that release of PBR bound cholesterol is inhibited and
therefore cleavage of the cholesterol to pregnenolone
5 is inhibited. Alternatively, a peptide comprising the
cholesterol interaction/recognition sequence can be
used to compete the cholesterol from its binding site
on the endogenous PBR receptor. This method is useful
for reducing disease symptoms resulting from increased
10 production of steroids, for example, stress and
Cushing's disease.

It is still another object of the present
invention to provide a method for increasing steroid
production in a steroidogenic cell, comprising
15 providing a PBR ligand to said cell such that PBR
releases cholesterol which is then available for
cleavage into pregnenolone and used as the precursor
of all steroids.

It is another object of the present invention to
20 provide a method for reducing steroid production in a
steroidogenic cell, comprising providing an agent
which inhibits PBR ligand binding to PBR such that
PBR-bound cholesterol is not released and said
cholesterol is not cleaved into pregnenolone, the
25 precursor of all steroids.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects, and advantages
of the present invention will become better understood
30 with reference to the following description and
appended claims, and accompanying drawings where:

Figure 1 shows effect of PBR ligands on MA-10
Leydig cell cholesterol transport and pregnenolone
formation. Mitochondria from MA-10 Leydig cells were
35 incubated with ³H-cholesterol in the presence or

absence of the indicated compounds. ^3H -Pregnenolone formed was measured as described in Materials and Methods. Data (means \pm SD) shown are representative of two to four independent experiments, each having
 5 triplicate assays. The effect seen was statistically significant at all times ($P < 0.001$).

Figure 2 A, B, and C show the expression of recombinant PBR in bacteria. Recombinant mPBR
 10 expression vector was developed and used to transform the BL21(DE3) *Escherichia coli* strain as described in Materials and Methods. The expression of recombinant mPBR protein was induced by 1 mM IPTG.

A) PBR protein expression was monitored by SDS-
 15 PAGE followed by Coomassie Blue staining or immunoblot analysis. 1, Control; 2 and 3, two different preparations of IPTG-treated bacteria.

B) Binding specificity of the IPTG-induced PBR in *Escherichia coli*. Specific binding of [^3H]PK11195
 20 (1.0 nM) was measured in the presence of the indicated concentrations of various ligands.

C) Scatchard representation of the specific binding of ^3H -PK11195 to IPTG-induced bacteria.

25 Figure 3. Characteristics of ^3H -cholesterol uptake by *E. coli* cells.

A) ^3H -Cholesterol uptake by *E. coli* cells was examined using increasing concentrations of control or IPTG-treated transformed bacteria incubated in the
 30 presence of 6.7 nM ^3H -cholesterol (50.0 Ci/mmol) for 60 min. at 37 C. Specific cholesterol uptake is defined as IPTG-induce minus basal values.

B) ^3H -Cholesterol specific uptake examined at the indicated temperatures using 100 ug bacterial protein.

C) Effect of energy poisons on ^3H -cholesterol uptake by IPTG-induced transformed bacteria.

D) PBR expression induces uptake of cholesterol only. Bacteria were incubated under the same
5 conditions as described above in the presence of the indicated radiolabeled steroid.

E) ^3H -cholesterol specific uptake determined in the presence of increasing concentrations of ^3H -cholesterol.

10 F) Ligand-induced release of cholesterol uptaken by the bacterial membranes. ^3H -Cholesterol-labeled membranes of IPTG-induced transformed bacteria were incubated with increased concentrations of PK11195 or clonazepam, and the ^3H -cholesterol released was
15 quantified. The results shown represent means \pm SD from an experiment performed in triplicate. Similar results were obtained in three other independent experiments.


Figure 4. Deletion mutation analysis of PBR
20 function-PK11195 ligand binding and ^3H -cholesterol uptake by bacteria transfected with the wild-type and mutated PBRs. The expression of the proteins was induced by IPTG. Left, The five transmembrane regions of PBR are shown as well as the location of the
25 deletions undertaken. Right, The effect of each deletion on PK11195 ligand binding and cholesterol uptake is shown. Results shown are the means of triplicates. 100% of PK 11195 ligand binding corresponds to 280 ± 22 fmol/mg protein. 100% of
30 specific cholesterol uptake corresponds to 1.35 ± 0.15 pmol/mg of protein.

Figure 5. Identification of specific amino acids responsible for the uptake of cholesterol. ^3H -Cholesterol uptake by bacteria transfected with the
35 wild-type and point-mutated PBRs (*bottom*). The

expression of the proteins was induced by IPTG. 100% of specific cholesterol uptake corresponds to 1.2 ± 0.1 pmol of cholesterol per mg of protein. Immunoblot analysis of the mutated PBRs expressed by the bacteria examined for ^3H -cholesterol uptake, (top). Results shown are the means of triplicates.

DETAILED DESCRIPTION

In one embodiment, the present invention relates to a minimum amino acid sequence specific for recognition/interaction with cholesterol, namely the amino acid sequence



wherein Z represents a neutral and hydrophobic amino acid, such as Leucine, Valine, Alanine, Isoleucine, Methionine, Phenylalanine and Tryptophan, Y represents a neutral and polar amino acid, such as Tyrosine, Threonine, Serine, Glycine, Glutamine, Cysteine, Asparagine, Q represents a basic amino acid, such as Arginine, Lysine, or arginine, and X represents any amino acids selected from the group consisting of Alanine (Ala, A), Arginine (Arg, R), Asparagine (Asn, N), Aspartic acid (Asp, D), Cystein (Cys, C), Glutamine (Gln, Q), Glutamic acid (Glu, E), Glycine (Gly, G), Histidine (His, H), Isoleucine (Ile, I), Leucine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Phenylalanine (Phe, F), Proline (Pro, P), Serine (Ser, S), Threonine (Thr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine (Val, V).

For example, some of the sequences of the present invention include:

Leu Asn Tyr Tyr Val Trp Arg (SEQ ID NO:1)

Leu Asn Tyr Cys Val Trp Arg (SEQ ID NO:2)

Leu Asn Tyr Arg (SEQ ID NO:3)

Val Ala Tyr His Gln Tyr **Tyr** Gln **Arg** (SEQ ID
NO:4)

The number of X amino acids can be from none
5 (zero) to five, preferably 1-5, more preferably 2-5,
and most preferably 3-5 amino acids. These amino
acids function to provide proper folding of this
consensus sequence to produce the recognition/
interaction site. All peptides herein are written
10 NH₂...COOH and the amino acids are the naturally
occurring L isomers.

Without being held to a particular theory,
studies suggest that Leucine or Valine in position Z
will interact with the hydrophobic side chain of
15 cholesterol and Tyrosine at position Y will interact
with the polar 3'OH-group of cholesterol, whereas the
Arginine or Lysine at position Q may help create a
pocket.

This cholesterol recognition/interaction amino
20 acid sequence consensus pattern was found in molecules
shown or suggested to interact with cholesterol, such
as apolipoprotein A-1 (Boyle, T. P. and Marotti, K.R.,
1992, *Gene* 117, 243-247), caveolin (Murata, M. et al.
1995, *Proc. Natl. Aca. Sci. USA* 92, 10339-10343), DBI
25 (Papadopoulos, V. 1993, *Endocr. Rev.* 14, 222-240;
Papadopoulos, V. 1998, *Proc. Soc. Exp. Biol. Med.* 217,
130-142), steroidogenesis acute regulatory protein
(StAR) (Stocco, D. M. and Clark, B. J. 1996, *Endocr.*
Rev. 17, 221-244), hedgehog protein (Porter, J. A. et
30 al. 1996, *Science* 274, 255-259), cytochrome P450
C26/25 (Su, P. et al. 1990, *DNA Cell Biol.* 9-657-667),
annexin II (Harder, T. et al. 1997, *Mol. Biol. Cell* 8,
533-545), sterol carrier protein-2 (Colles, S. M. et
al. 1995, *Lipids* 30, 795-803), cholesterol 7 α -
35 monooxygenase (Kai, M. et al. 1995, *Lipid Res.* 36,

367-374), cholesterol oxidase (Ishizaki, T. *et al.* 1991, *J. Bacteriol.* 171, 596-601), cholesterol dehydrogenase (Horinouchi, S. *et al.* 1991, *Appl. Environ. Microbiol.* 57, 1386-1393), bile-salt-activated lipase precursor (cholesterol esterase) (Nilsson, J. *et al.* 1990, *Eur. J. Biochem.* 192, 543-550), and acyl-CoA cholesterol acyltransferase (Pape, M.E. *et al.* 1995, *J. Lipid Res.* 36, 823-838) as shown in Table 1.

10

Table 1: Identification of the cholesterol recognition/interaction amino acid consensus pattern.

	Mouse PBR	149- VLNYVWR (SEQ ID NO:5)
	Rat PBR	150- LNYVWR (SEQ ID NO:6)
15	Human PBR	150- LNYCVWR (SEQ ID NO:7)
	Bovine PBR	149- LNYR (SEQ ID NO:8)
	Rat P450scc	88-VAYHQYYQR (SEQ ID NO:9)
	Human P450scc	88-VAYHQYYQR (SEQ ID NO:10)
	Pig P450scc	88-VAYHZHYQK (SEQ ID NO:11)
20	Mouse apolipoprotein A-I	210- LNEYHTR (SEQ ID NO:12)
	Mouse caveolin	94- VTKYWFYR (SEQ ID NO:13)
	Human hedgehog	251- VFYVIETR (SEQ ID NO:14)
	Mouse DBI	25- LFIYSHFK (SEQ ID NO:15)
25	Mouse StAR	6- LCAGSSYRHMR (SEQ ID NO:16)
	Rat Annexin II	145-VYKEMYKTDLEK (SEQ ID NO:17)
	Rat P450c26/25	424- VLCTYVVS (SEQ ID NO:18)
	Strept. cholesterol oxidase	420- VSLYLAIK (SEQ ID NO:19)
	Mouse cholesterol 7"-monooxygenase	167-VTEGMYAFCYR (SEQ ID NO:20)
30	Nocardia cholesterol dehydrogenase	91- VTEAYRQR (SEQ ID NO:21)
	Human Bile-Salt-Activated-Lipase	226- LSPYNKGLIR (SEQ ID NO:22)
	Rabbit acyl-CoA cholesterol acyltransferase	96- VVDYIDEG (SEQ ID NO:23)

The presence of the cholesterol interaction/
recognition consensus sequence in the proteins listed
in Table 1 signifies the likelihood that the proteins
interact with cholesterol and provides insight into
5 how these protein accomplish their functions in
concert with cholesterol and how to alter these
functions. For example, in the case of annexin which
is a calcium-phospholipid/cholesterol actin binding
protein important for various cell functions, i.e.
10 from maintaining cell membrane shape and stability to
facilitating the internalization of plasma membrane
components, altering the cholesterol
recognition/interaction site of annexin may result in
destabilization and collapse of the cytoskeleton.
15 This could be a useful method for targetting and
destroying tumor cell growth.

After reviewing the description of the present
invention, it would be within the skill of a person
with ordinary skill in the art to design mutant
20 proteins in which the cholesterol
recognition/interaction consensus sequence has been
altered such that the protein's ability to
interact/recognize cholesterol is reduced, increased,
or abolished. Experiments on these mutants will
25 further provide treatments for diseases associated
with an altered, reduced, or increased function of
these proteins, or even perhaps a method for targeting
specific proteins through their ability to interact
with cholesterol for altering the cholesterol
30 recognition/interaction function for a desired
purpose.

After reviewing the present disclosure, it will
be evident to a person with ordinary skill in the art
that it is possible to determine whether or not a
35 protein interacts with cholesterol or recognizes

cholesterol. This knowledge will provide insight into how a specific protein, whether known or yet to be discovered, functions or is regulated.

In another embodiment, the present invention provides a nucleotide sequence which encodes the amino acid sequences, or peptides described above. The nucleotides corresponding to codons specifying the amino acids of the consensus sequence described above are known to people in the art. These sequences can include for example:

Leu Asn Tyr Cys Val Trp Arg (SEQ ID NO:7).

The generation of nucleic acid molecules encoding the cholesterol interaction/recognition amino acid consensus sequence(s) described above is routine for a person with ordinary skill in the art. Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. Also included are chemically modified and substituted nucleic acids, e.g., those which incorporate modified nucleotide bases or which incorporate a labelling group.

The nucleic acid may be isolated. By "isolated" is meant a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid

molecules according to the present invention further include such molecules produced synthetically.

Such isolated nucleic acid molecules are useful for probes for detecting a gene which contains this
5 consensus sequence in a biological sample, for instance, by PCR, Southern blot, Northern blot, or other form of hybridization analysis as described in Molecular Cloning: A Laboratory Manual, 2nd edition, Sambrook, J. Fritsch, E.F. and Maniatis T., eds., Cold
10 Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) or DNA Cloning, Volumes I and II (D. N. Glover ed., 1985) or Current Protocols in Molecular Biology Ausubel, F. M. et al. (Eds.) John Wiley & Sons, Inc. for general cloning methods). The entire
15 disclosures of documents cited in this application are incorporated in their entirety by reference thereto. Typical nucleic acid probes may be prepared from the consensus amino acid sequences. In particular, probes may be prepared based upon segments of the amino acid
20 sequence which possess relatively low levels of degeneracy, i.e., few or one possible nucleic acid sequences which encode therefor. These probes may further comprise a detectable group for easy identification and location of complementary
25 sequences.

cDNA or genomic libraries of various types may be screened for new alleles or related sequences using the above probes. Phage or plasmid libraries may be used.

30 In addition to comprising a segment which encodes the peptides having the consensus sequence of the present invention, the nucleic acid of the present invention may also comprise a segment encoding a

heterologous protein, such that the gene is expressed to produce the two proteins as a fusion protein.

Nucleic acid molecules of the present invention which encode the amino acid consensus sequence of the present invention may include, but are not limited to those encoding the amino acid sequence of the consensus by itself; and additional coding sequences which code for additional amino acids, such as those which provide additional functionalities. Thus, the sequences encoding the consensus sequence may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide.

In addition to their use as probes, the nucleic acids of the present invention may also be used in the preparation of the peptides having the consensus amino acid sequence of the present invention.

DNA encoding the peptides with the consensus amino acid sequence of the present invention will typically be incorporated into DNA constructs capable of introduction to and expression in an *in vitro* cell culture. Often, the nucleic acids of the present invention may be used to produce a suitable recombinant host cell. Specifically, DNA constructs will be suitable for replication in a unicellular host, such as bacteria, e.g., *E. coli*, but may also be intended for introduction into a cultured mammalian, plant, insect or other eukaryotic cell lines. DNA constructs prepared for introduction into bacteria or yeast will typically include a replication system recognized by the host, the intended DNA segment encoding the desired polypeptide, transcriptional and translational initiation and termination regulatory sequences operably linked to the polypeptide encoding segment. A DNA segment is operably linked when it is

placed into a functional relationship with another DNA segment. For example, a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence; DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide. Generally, DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase. However, enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or adapters or linkers inserted in lieu thereof. The selection of an appropriate promoter sequence will generally depend upon the host cell selected for the expression of the DNA segment. Examples of suitable promoter sequences include prokaryotic, and eukaryotic promoters well known in the art and include promoters such as the *trp*, *lac* and phage promoters, tRNA promoters and glycolytic enzyme promoters, T7 promoter, T3 promoter, SP6 promoter, SV40 promoter, CMV promoter and MoMLV LTR are known and available. See Sambrook *et al.*, 1989, *supra*. The transcriptional regulatory sequences will typically include a heterologous enhancer or promoter which is recognized by the host.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof such as cosmids and phagemids.

Conveniently available expression vectors which include the replication system and transcriptional and translational regulatory sequences together with the insertion site for the consensus sequence peptide encoding segment may be employed. Among vectors preferred for use in bacteria include pBS vectors, Phagescript vectors, Bluescript vectors commercially available. Among preferred eukaryotic vectors are pSV2CAT, pWLNEO, available from Stratagene; and pSVK2, pMSG available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan such as pET vectors, such as pET15b, pZeoSV2, pCMV and the like. Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al. and in Metzger et al., *Nature* 334, 31-36, 1988. For example, where an insect host cell is selected as the host cell of choice to express the polypeptide, the cDNA encoding the polypeptides of the invention may be cloned into a baculovirus expression vector (pV-IKS). The recombinant baculovirus may then be used to transfect a suitable insect host cell, e.g. SF9 cells, which may then express the polypeptide. See, e.g. D.D. Morrison et al., *Cell* 58, 649-657, 1989, M.D. Summers and G.E. Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Station, College Station, Tex., 1987.

The vectors containing the DNA segments of interest, e.g. those encoding the peptides comprising the consensus sequence of the present invention, can be transferred into the host cell by well known methods, which may vary depending upon the type of host used. For example, calcium chloride transfection is commonly used for prokaryotic cells, whereas

calcium phosphate treatment may be used for other hosts. Introduction of the construct into the host cell can be effected by DEAE-dextran mediated transfection, cationic lipid-mediated transfection, 5 electroporation, transduction, infection, or other methods. See Davis et al. Basic Methods in Molecular Biology, 1986. The term "transformed cell" as used herein, includes the progeny of originally transformed cells.

10 In another embodiment, the present invention provides a cell stably transfected with a vector comprising the cholesterol interaction/recognition consensus sequence of the present invention. The term "transfected" as used herein refers to cell having 15 undergone the process of introduction of nucleic acid or a nucleic acid vector into a cell. Various methods of transfecting a cell are possible including microinjection, CaPO_4 precipitation, lipofection (liposome fusion), electroporation and use of a gene 20 gun. The term "stable" as used herein refers to the introduction of a gene into the chromosome of the targeted cell where it integrates and becomes a permanent component of the genetic material in that cell. A transfected cell containing a vector having a 25 peptide comprising the consensus sequence may only be transiently transfected, resulting in transient expression of the peptide. The term "transient" as used herein relates to the introduction of a gene into a cell to express a cholesterol consensus containing 30 peptide, where the introduced DNA is not integrated into the host cell genome and is accordingly eliminated from the host cell over a period of time. Transient expression relates to the expression of a product during a period of transient transfection. An

episomal transfection is a variant of stable transfection in which the introduced gene is not incorporated in the host cell chromosomes but rather is replicated as an extrachromosomal element. This
5 can lead to apparently stable transfection of the characteristics of a cell.

A cell may be transfected with a vector containing a selectable marker or cotransfected with a second vector containing the desired selectable
10 marker. This selectable marker is used to select those cells which have become transfected. Types of selectable markers which may be used are well known to those of ordinary skill in the art.

In another embodiment, there is provided a
15 transfected cell wherein a peptide comprising the cholesterol consensus sequence of the present invention is expressed as a cell surface peptide. By "cell surface" peptide is meant a peptide which wholly or partially spans the cell membrane, and which is
20 exposed on the surface of the cell. The peptide comprising the cholesterol consensus sequence of the present invention can be expressed as a secreted peptide. By "secreted peptide" is meant a peptide which is not associated with the cell membrane, but
25 rather is intracellularly processed for secretion into the extracellular environment or other cellular compartment.

The peptide comprising the consensus amino acid sequence of the present invention can be recovered and
30 purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction
35 chromatography, affinity chromatography,

hydroxylapatite chromatography, lectin chromatography, and high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells.

10 An additional preferred embodiment provides for a transgenic animal containing a cholesterol interaction/recognition consensus sequence nucleic acid. The consensus sequence can also be presented on a vector alone, or as part of a gene. By "transgenic animal" is meant an animal whose genome contains an additional copy or copies of the desired gene from the same species or another species introduced by genetic manipulation or cloning techniques, as described herein and as known in the art. The transgenic animal can include the resulting animal in which the vector has been inserted into the embryo from which the animal developed or any progeny of that animal. The term "progeny" as used herein includes direct progeny of the transgenic animal as well as any progeny of succeeding progeny. Thus, one skilled in the art will readily recognize that if two different transgenic animals have been made each utilizing a different gene or genes and they are mated, the possibility exists that some of the resulting progeny will contain two or more introduced genes. One skilled in the art will readily recognize that by controlling the matings, transgenic animals containing multiple introduced genes can be made. This transgenic animal is useful in screening compounds for their pharmacological

effects on cholesterol interaction, recognition,
uptake and metabolism in the transgenic animal.

In another embodiment, the present invention
provides a transgenic insect. Studies have shown that
5 PBR is found in insects and is homologous to the
mammalian PBR. Therefore, using methods known in the
art, it is possible to introduce a mutation in the
genomic PBR sequence as described above such that the
ability of PBR to recognize or interact with
10 cholesterol is abolished or reduced, or increase
steroid production by introducing an additional
cholesterol interaction/recognition sequence. The
ability to control the production of steroids in
insects by controlling the uptake of cholesterol
15 through PBR represents a powerful method for
controlling insect reproduction.

In another embodiment of the present invention is
provided a transgenic plant comprising in its genome a
a nucleic acid encoding the cholesterol
20 interaction/recognition sequence or an altered
cholesterol interaction/recognition sequence wherein
cholesterol interaction is reduced, abolished or
increased. The cholesterol interaction/recognition
sequence can be delivered alone or as part of a gene,
25 or in a vector alone or as part of a gene. Evidence
indicates that the PBR receptor in plants functions
similarly to the mammalian PBR and is homologous in
sequence. Therefore, it is another aspect of the
invention to provide a transgenic plant comprising in
30 its genome a genetic construct comprising a nucleic
acid encoding PBR with an altered cholesterol
recognition/interaction sequence wherein the ability
of PBR to interact with cholesterol and channel it
into the cell is reduced, abolished, or increased
35 thereby resulting in a reduced, abolished or increased

uptake of cholesterol in the cell, and/or reduced, abolished, or increased production of steroids in the transgenic plant. This method may offer an opportunity to regulate cholesterol levels in plants, an well as specific plant steroids such as cardenolides, etc. required for nutrition or any other purpose. Research has demonstrated that transgenic plants are capable of passing on the inserted genes to their progeny by normal Mendelian inheritance (Christou et al., 1990, *Trends in Biotechnol.* 8, 145-151). All such progeny plants which inherit the inserted genetic construct are also transgenic plants as the term is used here.

The production of transgenic plants is known in the art. Please see for example, U.S. Patent No. 5,869,720 to John, M.E. issued on February 9, 1999, and U.S. Patent No. 5,859,347 to Brown et al. issued on January 12, 1999. The disclosures of both patents are hereby incorporated in their entirety by reference thereto.

Briefly, the nucleic acid desired can be inserted into a suitable plant transformation vector for transformation into the desired plant species. Suitable plant transformation vectors include those derived from a *Ti* plasmid of *Agrobacterium tumefaciens*. A plant transformation vector preferably includes all of the necessary elements needed for transformation of plants, or plant cells. Specific plant tissues can be targeted by using promoters specific for expression in fruit, fiber, root, etc... Promoters used can be inducible by plant hormone such as ecdysone, by antibiotic, such as tetracycline, by changes in temperature, such as heat shock elements. Typical plant transformation vectors comprise selectable marker genes, one or both of the T-DNA

borders, cloning sites, appropriate bacterial genes to facilitate identification of transconjugates, broad host-range replication and mobilization functions and other elements as desired.

5 Transformation of plant cells may be effected by delivery of a transformation vector or of free DNA by use of a particle gun which comprises high velocity microprojectiles coated with the vector into plant tissue. Selection of transformed plant cells and
10 regeneration into whole plants may be carried out using conventional procedures. Other transformation techniques capable of inserting the desired gene or nucleic acid into plant cells may be used, such as electroporation or chemicals that increase free nucleic
15 acid uptake. Illustrative examples of methods suitable for regenerating transgenic plants are : corn (Fromm et al., 1990, *Bio/Technology* 8:833-839; and Gordon-Kamm et al., 1990 *The Plant Cell* 2:603-618); rice (Wang et al., 1988, *Plant Mol. Biol.* 11:433-439)
20 and wheat (Vasil et al., *Bio/Technology* 8:743-747).

 In one aspect, the transformed or transfected cells are useful for screening agents or drugs which alter the ability of polypeptides comprising the consensus sequence and mutants of said sequence to
25 interact, recognize or bind to cholesterol or its derivatives. An *in vitro* system for determining whether a compound, drug, or agent is an agonist or antagonist of the ability of the polypeptide comprising the consensus sequence of the present
30 invention to interact with cholesterol can be designed. A polypeptide comprising the consensus sequence of the present invention can be incubated along with cholesterol under conditions, i.e. salts, pH, lipid, ions, where interaction between cholesterol
35 and the peptide comprising the consensus sequence

occurs, . The complex may then be incubated with a test compound. Interaction between the polypeptide and cholesterol may then be measured. An increase or decrease in the level of interaction between the polypeptide and cholesterol in response to a particular compound would indicate that the compound is an agonist or antagonist of that binding, respectively.

The same test can be administered on cells which express a polypeptide comprising the cholesterol interaction/recognition consensus sequence. The pH and temperature which are most effective for cholesterol interaction are preferably used but it is possible to replicate the conditions found in a diseased cell for testing the effect of a particular drug with respect to a proposed therapy for the disease.

A test compound may be a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials such as bacteria, plants, fungi, or animal cells or tissues.

For many of the methods of the present invention, the polypeptides and nucleic acids of the invention may be covalently attached or linked to a detectable group to facilitate screening and detection. Useful detectable groups or labels, are generally well known in the art. For example, a detectable group may be a radiolabel, such as, ^{125}I , ^{32}P , or ^{35}S , or a fluorescent or chemiluminescent group. Alternatively, the detectable group, may be a substrate, cofactor, inhibitor, affinity ligand, antibody binding epitope tag, or an enzyme which is capable of being assayed. Suitable enzymes include, e.g., horseradish peroxidase, luciferase, or another readily assayable

enzymes. These enzyme groups may be attached to the polypeptide comprising the consensus sequence by chemical means or expressed as a fusion protein as already described.

5 In another embodiment, the present invention provides a method for detecting presence, absence, increase or decrease of cholesterol or a derivative of cholesterol in a biological sample. This can be done in several ways, for example, in some instances, it
10 may be useful to immobilize the polypeptide comprising the consensus sequence upon a solid support, e.g., a microtiter well, or nitrocellulose membrane. The sample to be assayed is exposed to the immobilized polypeptide, and the amount of cholesterol-bound
15 polypeptide is measured.

Alternatively, the present invention provides a method for detecting the presence of a polypeptide comprising the consensus sequence of the present invention by coating on a solid support cholesterol or
20 a derivative of cholesterol capable of interacting with the peptide comprising the cholesterol interaction/recognition sequence, and exposing said cholesterol or its derivative to a sample thought to contain a polypeptide(s) comprising the consensus
25 sequence of the present invention and detecting cholesterol-bound polypeptide. For detection of an increase or decrease in the level of cholesterol, or a derivative of cholesterol, comparison to appropriate controls may be necessary.

30 The solid support can include agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose, polystyrene, filter paper, nitrocellulose, ion exchange resins, plastic films, glass beads, polyaminemethylvinylether maleic acid copolymer, amino
35 acid copolymer, ethylene-maleic acid copolymer, nylon,

5 silk, etc. The support may be in the form of, e.g., a test tube, microtiter plate, beads, test strips, or the like. The reaction of the solid support with either cholesterol or the polypeptide may be carried out by methods well known in the art.

10 By "biological sample" is intended any biological sample obtained from an animal, cell line, tissue culture, plant, insect, or other source which may contain cholesterol or its derivatives, or cholesterol interacting/recognizing polypeptides mRNA or DNA. Biological samples include body fluids (such as saliva, blood, plasma, urine, mucus, synovial fluid, etc.) tissues (such as muscle, skin, and cartilage) and any other biological source suspected of
15 containing cholesterol or derivatives of cholesterol, or cholesterol binding polypeptides or nucleic acids. Methods for obtaining biological samples such as tissue are well known in the art.

20 In another embodiment, the present invention provides a method for identifying whether or not a protein recognizes or interacts with cholesterol or cholesterol derivatives said method comprising identifying the presence or absence of the above-mentioned cholesterol recognition/
25 interaction consensus by analyzing the cholesterol interaction/ recognition amino acid sequence of the unknown protein as discussed in the examples below. The presence of the amino acid sequence of the present invention is an indication of the likelihood that the
30 protein recognizes/interacts with cholesterol or a cholesterol derivative.

In another embodiment, the present invention provides a method for conferring to a molecule the ability to interact with cholesterol or a cholesterol
35 derivative which is recognized by the cholesterol

recognition/interaction sequence. Since the consensus sequence for interaction/recognition of cholesterol has been elucidated, it is now possible to introduce into a molecule or polypeptide, natural or synthetic, a cholesterol recognition/interaction sequence such that the protein or polypeptide, natural or synthetic, is now able to recognize/interact with cholesterol or a cholesterol derivative. The consensus sequence can be introduced at the DNA or RNA level, by inserting the nucleotide sequence encoding the consensus sequence into a part of the gene for said molecule, such that the consensus sequence is translated along with the molecule and together they form a fusion protein. Preferably, the consensus sequence is inserted at the amino or carboxy terminal of the gene such that secondary and tertiary folding of the gene product does not inhibit the interaction of the consensus sequence with cholesterol. The fusion protein can be tested for its ability to interact/recognize or bind cholesterol or a cholesterol derivative.. These fusion proteins can be used for therapy or diagnostics. The molecule into which the cholesterol interaction/recognition sequence is desired can be natural or synthetic.

In yet another embodiment, the present invention provides a molecule which blocks the cholesterol interaction/recognition ability of a peptide comprising the cholesterol recognition/interaction consensus described above to recognize/interact with cholesterol. The molecule can be an antibody, a peptide, or drug. Antibody production using peptides is well known in the art, see, e.g., Sutcliffe, *et al.* *Science* 219, 660-666, 1983; Wilson *et al.*, *Cell* 37, 767-778, 1984, and Bittle *et al.*, *J. Gen. Virol.* 66, 2357-2354, 1985. As used herein, the term "antibody"

(AB) or "monoclonal antibody (Mab) is meant to include intact molecules, single chain whole antibodies, and antibody fragments. Antibody fragments of the present invention include Fab and F(ab')₂ and other fragments including single chain Fvs (scFv) and disulfide-linked Fvs (sdFv). Also included in the present invention are chimeric and humanized monoclonal antibodies and polyclonal antibodies specific for the polypeptides of the present invention. The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing a polypeptide of the present invention or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. Monoclonal antibodies can be prepared using hybridoma technology known in the art see, e.g., Harlow et al., Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press 2nd ed., 1988). Additionally, antibodies capable of binding to a polypeptide antigen of the present invention may be produced through the use of anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and that, therefore, it is possible to obtain an antibody which binds to a second antibody.

Additionally, the cholesterol interaction/recognition peptide may be useful in modeling small molecules which interfere with cholesterol binding *in vivo*. In particular, the structure of the cholesterol interaction/recognition domain from the known amino acid sequence and the 3-dimensional structure, which may be determined by x-ray crystallographic methods known in the art, may be applied in generating synthetic analogs, cholesterol derivatives, and mimics of the particular cholesterol

interaction/recognition domain. Synthetic elements may be pieced together based upon their analogy to the structural and chemical aspects of the cholesterol interaction/recognition domain. Such mimics, analogs, and derivatives may be used in blocking or inhibiting specific functions resulting from cholesterol binding to a peptide or gene product. These functions can vary since a role for cholesterol has been implicated in cell signaling, cell proliferation, gene regulation, cytoskeletal anchoring and stability, neural transmission, fertility, stress, diabetes, stroke, to name a few, and may thus be useful as therapeutic treatments according to the methods described herein.

The present invention includes both bio chips and biosensor comprising polynucleotides, polypeptides, and antibodies of the present invention and methods of their use. Bio chips comprising arrays of polynucleotides, polypeptides, and antibodies of the present invention may be used to detect the presence of same in a biological or environmental sample and to diagnose an animal, including human. Methods and particular uses of the polynucleotides of the present invention to detect the same using bio chip technology include those known in the art and those of: U.S. Patent Nos. 5510270, 5677195, 5607646 and World Patent Nos. WO97/10365, WO97/43447, each incorporated herein in their entireties.

Biosensors using the polynucleotides, polypeptides and antibodies of the present invention may also be used to detect, monitor, and diagnose. Methods and particular uses of the polynucleotides, polypeptides and antibodies of the present invention using biosensors include those known in the art and those of: U.S. Patent Nos. 5721102, 5658732, and World

Patent Nos. WO97/35011, WO97/20203, each incorporated herein in their entirety.

In another embodiment, the present invention relates to a method for altering the cholesterol binding ability of molecules which contain the cholesterol recognition/interaction consensus described above, comprising altering said site such that cholesterol recognition is reduced, eliminated, or increased. Increased cholesterol recognition occurs when the cholesterol pocket is perfectly formed or by introducing into a molecule a new or additional cholesterol recognition/interaction sequence. We have been able to produce PBR with reduced or no ability to recognize and interact with cholesterol by modifying the cholesterol recognition/interaction site of PBR, for example by changing amino acid 153 from tyrosine to serine, or by changing amino acid 155 from arginine to leucine. These modifications are expected to produce similar results in species which express PBR, and on proteins other than PBR which contain the consensus sequence. Therefore, it would be possible to alter the cholesterol recognition/interaction ability of a polypeptide comprising the peptide consensus sequence of the present invention by changing the tyrosine in the consensus sequence to serine or other amino acid with no charge, for example, or changing the consensus sequence arginine to leucine or any other amino acid without a charge.

In this application is described the consensus sequence for a cholesterol interaction/recognition site first discovered on PBR. In addition to the presence of PBR in the mitochondrial membrane, PBR is present in the plasma membrane (Oke, B. O. *et al.* 1992, *Mol. Cell. Endocr.* 87:R1-R6; Garnier, M. *et al.* 1993, *Endocrinology* 132:444) and in the nuclear

membrane (Hardwick, M. et al. 1999, *Cancer Research* 59:831-842). Results reported in this application indicate that the carboxy terminal of the receptor is responsible for the interaction and subsequent uptake of cholesterol. Cholesterol is released from the receptor once a ligand binds to the amino terminal portion of the receptor. In the case of the mitochondria, the cholesterol is released into the inner mitochondrial membrane where it is available for interaction with P450scc and is cleaved to produce pregnenolone in steroidogenic cells. Pregnenolone is the precursor of steroids.

Therefore, the present invention relates to a method for increasing cholesterol in the membrane of a cell by inhibiting its release from the receptor, PBR. Alternatively, a method is provided for decreasing the presence of cholesterol inside the cell by introducing an agent which inhibits PBR ligand binding to PBR thereby inhibiting the release of cholesterol from PBR.

In another embodiment, the present invention relates to a method for increasing the presence of cholesterol inside the cell by introducing a PBR ligand such that the cholesterol is released from PBR.

In steroidogenic cells, an increase in the release of cholesterol from PBR due to ligand binding would result in an increase in pregnenolone production. Therefore, a method is provided for increasing pregnenolone production in a steroidogenic cell, comprising providing a PBR ligand to said cell such that PBR releases cholesterol which is then available for cleavage into pregnenolone. The peptide can be targeted to specific steroid producing cells by complexing it with leutinizing hormone for targeting to the testes, with follicle stimulating hormone for

targeting to the ovaries, and with ACTH for targeting to the adrenal. Conversely, a method for decreasing pregnenolone production in a steroidogenic cell, comprising providing a PBR ligand inhibitor to said
5 cell such that release of PBR bound cholesterol is inhibited and therefore cleavage of the cholesterol to pregnenolone is inhibited.

Since pregnenolone is the precursor for steroid production, a method for increasing steroid production
10 in a steroidogenic cell, comprising providing a PBR ligand to said cell such that PBR releases cholesterol which is then available for cleavage into pregnenolone and used as the precursor of all steroids. Similarly, a method for reducing steroid production in a
15 steroidogenic cell, comprising providing an agent which inhibits PBR ligand binding to PBR such that PBR-bound cholesterol is not released and said cholesterol is not cleaved into pregnenolone, the precursor of all steroids. This method is useful for
20 reducing disease symptoms resulting from increased production of steroids such as stress and Cushing's disease.

In addition to the above described uses, the polypeptides and nucleic acids of the present
25 invention may also be used in therapeutic applications for the treatment of human or non-human mammalian patients.

The nucleic acid encoding the polypeptide comprising the cholesterol interaction sequence of the
30 present invention can be used as a cholesterol acceptor in order to regulate the amount of cholesterol, or cholesterol derivatives, in a tissue or blood. The nucleic acid is administered alone or as part of a vector such that it is translated, and
35 the resulting polypeptide is capable of interacting

with/binding to cholesterol. The nucleic acid sequence encoding a peptide comprising the cholesterol interaction/recognition consensus sequence can be administered prophylactically, or to patients having a disease or condition characterized by an elevated plasma cholesterol level. By "elevated level" is meant a higher level relative to what is normally found in the plasma. Administration can be by exogenous delivery of the nucleic acid as naked DNA, DNA associated with specific carriers, or in a nucleic acid expression vector to a desired tissue by means of an appropriate delivery vehicle, e.g. a liposome, by use of iontophoresis, electroporation and other pharmacologically approved methods of delivery. Some methods of delivery may include: encapsulation in liposomes, transduction by retroviral vectors, localization to nuclear compartment utilizing nuclear targeting site found on most nuclear proteins, transfection of cells *ex vivo* with subsequent reimplantation or administration of the transfected cells, a DNA transporter system. Intravenous administration with a drug carrier designed to increase the circulation half-life of the nucleic acid encoding the cholesterol interaction/recognition sequence can be used. Additionally, the treatment of any disorder may comprise gene therapy techniques involving the cholesterol interaction/recognition domain sequence or a mutation or alteration of the cholesterol interaction/recognition domain sequence. Strategies for gene therapy are reviewed in Friedman, *Science* 244, 1275, 1989.

Drug delivery vehicles are effective for both systemic and topical administration. They can be designed to serve as a slow release reservoir, or to deliver their contents directly to the target cell.

An advantage of using direct delivery drug vehicles is that multiple molecules are delivered per uptake. Such vehicles have been shown to increase the circulation half-life of drugs which would otherwise be rapidly cleared from the blood stream. Some examples of such specialized drug delivery vehicles are liposomes, hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres.

The nucleic acid sequence encoding a cholesterol recognition/interaction sequence may also be systemically administered. Systemic absorption refers to the accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include: intravenous, intramuscular, subcutaneous, intraperitoneal, intranasal, intrathecal and ophthalmic. A gene gun may also be utilized. The dosage will depend upon the disease indication and the route of administration but should be between 1-1000 ug/kg of body weight/day. The duration of treatment will extend through the course of the disease symptoms, possibly continuously. The number of doses will depend upon disease delivery vehicle and efficacy data from clinical trials.

The nucleic acid comprising the cholesterol interaction/recognition consensus sequence may be administered utilizing an *in vivo* approach whereby the nucleic acid will be administered directly to an animal by intravenous injection, intramuscular injection, or by catheterization and direct delivery of the nucleic acid via the blood vessels and directed to a target organ by using tissue-specific promoters.

The polypeptides of the present invention may be used to inhibit or block uptake of cholesterol into cells by competing for cholesterol. These methods may

generally be used in the treatment of a variety of diseases resulting from an increase in cholesterol in the cell or in the plasma, or in screening compounds effective for such treatment. Cholesterol is required

5 for normal cell growth and proper membrane structure and function. Unregulated accumulation of cholesterol is cytotoxic and a failure to maintain cholesterol homeostasis results in a number of pathological states (See: Subcellular Biochemistry vol. 28, *Cholesterol: its Functions and Metabolism in Biology and Medicine*. Bittman, Robert (Ed), Plenum Press, N.Y.). Specific disorders include gallstones, atherosclerosis, Niemann-Pick C, Sitosterolemia, Dystrophy, Tumor proliferation (tumorigenesis), Schnyder's corneal

10 crystalline dystrophy. Brain disorders include cholesterol metabolism and Alzheimer's disease, Tellurium toxicity, Smith-Lemli-Opitz syndrome, myelinization, developmental abnormalities and demyelization : Charcot-Marie-Tooth disease;

15 Pelizaeus-Merzbacher disease, Multiple sclerosis, SLA, to name a few. Alternatively, the methods and compositions may be useful as prophylactic treatment, or in screening for compounds effective in prophylactic treatments.

20 In another aspect of the invention, the peptide comprising the cholesterol recognition/interaction consensus sequence of the present invention can be used to deliver, when needed, cholesterol, or a cholesterol derivative which binds the cholesterol

25 recognition/interaction sequence of the present invention. The peptide can be complexed to cholesterol prior to administration, thereby avoiding the nonspecific attachment of cholesterol to other factors such as albumin for example.

30

37

The quantities of reagents necessary for effective therapy, also referred to herein as an "effective amount", or "therapeutically effective amount", will depend upon many different factors, including means of administration, target site, Physiological state of the patient and other mdicants administered. Thus, treatment doses will need to be titrated to optimize safety and efficacy. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Generally, therapeutically effective amounts of the polypeptide comprising the cholesterol interaction/recognition domain of the present invention will be from about 0.0001 to about 100 mg/kg, and more usually, from about 0.001 to about 0.1 mg/kg of the subject's body weight. Various considerations are described, e.g., in Gilman et al., (Eds.), Goodman and Gilman's: The Pharmacological Basis of Therapeutics, (8th ed., 1990), Pergamon Press, and Remington's Pharmaceutical Sciences (7th ed., 1985) Mack Publishing Co., Easton, Pa. Methods of administration, also discussed in the above references, include, e.g., oral, intravenous, intrperitoneal or intramuscular administration, and local administration, including topical, transdermal diffusion and aerosol administration, for therapeutic, and/or prophylactic treatment. The active agent will generally be administered in a composition additionally comprising a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds

described in, e.g., the Merck Index, Merck and Co.,
Rahway, N.J.

By "subject" is meant fish, animals, including
plants, insects, monkeys, apes, cats, dogs, birds,
5 cows, pigs, mice, horses, rabbits and humans.

Constituents of pharmaceutical compositions, in
addition to the active agents, include those generally
known in the art for the various administration
methods used. For example, oral forms generally
10 include powders, tablets, pills, capsules, lozenges
and liquids. Similarly, intravenous, intraperitoneal
or intramuscular formulations will generally be
dissolved or suspended in a pharmaceutically acceptable
carrier, e.g., water, buffered water, saline, and the
15 like. Additionally, these compositions may include
additional constituents which may be required to
approximate physiological conditions, such as pH
adjusting and buffering agents, toxicity adjusting
agents, wetting agents and the like. For solid
20 compositions, conventional nontoxic solid carriers may
be used which include, e.g., pharmaceutical grades of
mannitol, lactose, starch, magnesium stearate, sodium
saccharin, talcum, cellulose, glucose, sucrose,
magnesium carbonate, and the like.

25 Administration may also be carried out by way of
a controlled release composition or device, whereby a
slow release of the active ingredient allows
continuous administration over a longer period of
time.

30 The following MATERIALS AND METHODS were used in
the examples that follow.

MA-10 Leydig cells- MA-10 mouse Leydig tumor
cells were maintained as we previously described
(Papadopoulos, V. et al. 1990, *J. Biol. Chem.*
35 265:3772-3779). For the cholesterol uptake assays,

mitochondria were isolated as we described
(Papadopoulos et al. 1990, *supra*; Krueger and
Papadopoulos, 1990, *supra*) and resuspended in buffer A
(250mM Sucrose, 20mM KCl, 15mM triethanolamine
5 hydrochloride [pH7.0], 10mM K₃PO₄ and 10mM MgCl₂) at
1mg/ml total protein concentration (Leaver, H. A. and
Boyd G. S. 1981, *J. Endocrinol.* 91:123-133).
Mitochondria were then incubated with [1,2-³H]-
cholesterol (0.127 uCi/100 nmol) in 0.3 ml buffer A at
10 37 °C (or the indicated temperature) for the indicated
time period. At the end of the incubation, steroids
were extracted and ³H-pregnenolone formed was isolated
by thin layer chromatography and quantified (Amri, H.
et al. 1996, *Endocrinology* 137:5707-5718).

15

*Construction of the mouse PBR expression vector
(pET15bPBR) and Expression of Recombinant PBR in
bacteria-* The pET system (Novagen, Madison, WI) was
used to express the MA-10 mouse PBR (mPBR) recombinant
20 protein. The insert containing full length coding
sequence as well as the NdeI and XhoI site extensions
at the 5' and 3' ends were generated by PCR using the
following primers: ATATATACATATGCCTGAATCCTGGGTG (SEQ
ID NO:24) and ATACTCGAGTGGGTGCCTTCACTCTG (SEQ ID
25 NO:25), respectively. The MA-10 full length PBR cDNA
(Garnier, M. et al. 1994, *Mol. Pharm.* 45:201-211) was
used as template. This mPBR fragment was inserted into
pET15b vector and linearized with NdeI and XhoI
downstream of the T7lac promoter. Recombinant mPBR
30 expression vector was used to transform the BL21(DE3)
Escherichia coli strain (Novagen) where the expression
of recombinant mPBR protein was induced by 1mM
isopropyl-1-thiol-β-D-galactopyranoside (IPTG). PBR
protein expression was monitored by SDS-PAGE followed
35 by Coomassie Blue staining or immunoblot analysis

using anti-PBR antiserum (Amri *et al.* 1996, *supra*). Binding specificity of the IPTG-induced PBR in *E. coli* was determined in binding studies where specific binding of ^3H -PK 11195 (1.0 nM) was measured in the
 5 presence of the indicated concentrations of the indicated ligands.

^3H -Cholesterol uptake by *E. coli* cells was examined using the indicated concentrations of control or IPTG-treated transformed bacteria incubated in the
 10 presence of 6.7 nM ^3H -cholesterol (50.0 Ci/mmol) for 60 min at 37°C. Specific cholesterol uptake is defined as IPTG-induced minus basal values. *E. coli* protoplasts were prepared from cells grown in LB at 37°C to the logarithmic phase of growth and
 15 centrifuged at 10,000g for 5 min. The cells were washed twice in 10mM Tris-HCl buffer [pH8.0] and the pellet was resuspended in a solution containing 20%(w/w) sucrose and 0.1M Tris-HCl [pH8.0]. The cells were then suspended in 1ml of buffer per 10 OD₄₅₀ and
 20 mixed. Within 1 min lysozyme was added from a 2mg/ml stock solution in distilled water to a final concentration of 100 ug/ml at 37°C, and stirring was continued for the next 12 min. The cell suspension was diluted 1:10 with 0.1M Na₂EDTA prewarmed to 37°C.
 25 Continuous stirring and slow dilution over 2.5 min prevented cell lysis. More than 99% of the cells became spherical within 10 minutes (Weiss, R. L. 1978, *Meth. Cell Biol.*20:141-147). Protoplasts (100 ug in 0.3 ml final volume) were then incubated in the
 30 presence of 6.7 nM ^3H -cholesterol (50.0 Ci/mmol) for 60 min at 37°C for cholesterol uptake assays. ^3H -Cholesterol-labeled membranes of IPTG-induced transformed bacteria, incubated with 30 nM ^3H -cholesterol, were treated with PK 11195 or clonazepam

and the ^3H -cholesterol released was quantified by liquid scintillation spectrometry.

Site-directed Mutagenesis- Mutations were performed using the QuikChange Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA). Briefly, miniprep pET-PBR plasmid dsDNA was used as template. Synthetic oligonucleotide primer pairs containing A147T, Y153S, R155L point mutations and PBR deletions, Δ 5-20, Δ 41-51, Δ 108-119, Δ 120-133, Δ 141-152, Δ 153-169, each complementary to the opposing strand of the vector, were extended during temperature cycling by *pfu* DNA polymerase. Upon incorporation of the oligonucleotide primers, mutated plasmids containing staggered nicks were generated. After temperature cycling, the products were treated with *Dpn* I is used to digest the parental DNA template and select for the generated mutation. The nicked vector DNAs containing the desired mutations were then transformed into *E. coli*. The mutated plasmids were prepared by ABI Prism Miniprep Kit. The generated mutations and deletions were confirmed by sequencing using the ABI Prism Dye Terminator Cycle Sequencing ready reaction kit (Perkin Elmer Applied Biosystems, Foster City, CA). DNA sequencing was performed at the Lombardi Cancer Center Sequencing Core Facility (Georgetown University).

Radioligand binding assays- ^3H -1-(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinolinecarboxamide (PK 11195) binding studies were performed as we previously described (Papadopoulos, V. et al. 1990, *J. Biol. Chem.* 265: 3772-3779; Garnier, M. et al. 1994, *Mol. Pharm.* 45:201-211). The dissociation constant (K_d) and the

number of binding sites (B_{max}) were determined by Scatchard plot analysis of the data using the LIGAND program (Munson, P. J. and Rodbard, D. 1980, *Anal. Biochem.* 107:220-239).

5

Protein measurement- Microgram amounts of protein were quantified using the dye-binding assay of Bradford (Bradford, M. M. 1976, *Anal. Biochem.* 72:248-254) using bovine serum albumin as the standard.

10

Statistics- The results shown represent the means \pm S.D. or S.E.M. from 2 to 6 independent experiments. Statistical analysis was performed by ANOVA followed by the *Student-Newman-Keuls* test or the *Dunnett* multiple comparisons test using the Instat (v.2.04) package from GraphPad, Inc. (San Diego, CA).

15

Example 1

20

A three-dimensional model of human PBR was built using molecular dynamics simulations and shown to accommodate a cholesterol molecule within its five helices (Bernassau, J. M. *et al.* 1993, *J. Mol. Graph.* 11:236-245). Despite differences in the primary amino acid sequence between the human and mouse PBR, similar data was obtained when the mouse 18 kDa PBR protein was submitted to the same analysis (Papadopoulos, V. 1996, *supra*), further suggesting that PBR may function as a channel for Cholesterol. In order to test this hypothetical model we used two cell model systems:

25

30

(i) the MA-10 Leydig cells, a steroidogenic cell model which expresses high levels of PBR (~40 pmol/mg protein; Papadopoulos, V. *et al.* 1990, *J. Biol. Chem.* 265:3772-3779), and as all eukaryotic cells contains endogenous cholesterol; and (ii) the *E.coli* DE3 cells

which do not express PBR (this study), do not have
endogenous cholesterol (Moat, A.G. and Foster, J.W.
1995, Microbial Physiology. Wiley-Liss, New York.) and
do not form steroids. Thus, using these cell models
5 we attempted to correlate PBR expression with the
cholesterol transport function. In addition, we used
a method with radiolabeled cholesterol (Leaver, H. A.
and Boyd G. S., 1981, *J. Endocrinol.* 91:123-133) to
quantify cholesterol movement. This method allows for
10 the distinction between the exogenously supplied
cholesterol and the endogenous cholesterol, permitting
an easy quantification, and direct measurement of the
pregnenolone formed, in the case of the steroidogenic
cells where cholesterol transported to IMM is cleaved
15 by the P450_{scc} to generate pregnenolone. Data shown
in Fig. 1 validate the use of this method. Fig.1
shows that in the steroidogenic Leydig cells, ³H-
cholesterol uptake by the mitochondria and transport
from OMM to IMM were stimulated by specific PBR
20 ligands resulting in increased ³H-pregnenolone
formation. These data are in agreement with previous
findings in all steroid synthesizing cell types of the
body (Papadopoulos, V. 1993, *Endocr. Rev.* 14:222-
240; Papadopoulos, V. 1998, *Proc. Soc. Exp. Biol. Med.*
25 217:130-142). Moreover, a similar PBR-dependent
cholesterol transport mechanism from OMM to IMM was
recently identified in liver mitochondria (Tsankova,
V. et al., 1995, *Eur. J. Pharm.* 294:601-607).
Cholesterol transport to liver IMM may be required for
30 cholesterol detoxification from the periphery by the
IMM sterol-27-hydroxylase (Tsankova et al., 1995,
supra). Interestingly, the rate of cholesterol uptake
and intramitochondrial transport to IMM, in response
to PBR ligand activation, was identical (0.9 nmol/mg
35 protein/min) for adrenal (Krueger, K.E. and

Papadopoulos, V. 1990, *J. Biol. Chem.* 265:15015-15022) and liver (Tsankova et al. 1995, *supra*) mitochondria, suggesting that a similar PBR-mediated cholesterol transport mechanism is operative in both steroidogenic and non-steroidogenic tissues.

As noted above a bacterium is a model system without endogenous cholesterol (Moat and Foster, 1995, *supra*). In addition, bacteria do not express PBR protein (Fig. 2A) and ligand binding (not shown) although the presence of a PBR homologous protein, the tryptophan-rich-sensory-protein *tspO* (also called *crtK*), involved in carotenoid biosynthesis in *Rhodobacter capsulatus* and *Rhodobacter sphaeroides* photosynthetic bacteria, has been reported (Yeliseev, A.A. and Kaplan S. 1995, *J. Biol. Chem.* 270:21167-21175). *Escherichia coli* were transfected with mouse PBR cDNA in a pET vector. Addition of IPTG to transfected bacteria resulted in the expression of the 18 kDa PBR protein (Fig. 2A) and ligand binding (Fig. 2B; $K_d=1.1$ nM and $B_{max}=0.23$ pmol/mg protein) with similar pharmacological characteristics to that previously described for PBR (Papadopoulos, 1993, *supra*; Papadopoulos, V. et al. 1990, *supra*) (Fig. 2C). IPTG-induced PBR expression resulted in a protein (Fig. 3A), time (Fig. 3B), and temperature-dependent uptake of radiolabeled cholesterol (Fig. 3B). This cholesterol uptake was maintained when protoplasts were prepared indicating that PBR resides in the internal bacterial plasma membrane (data not shown). The uptake of cholesterol could not be blocked by energy poisons (DeGrella, R. F. and Simoni, R. d., 1982, *J. Biol. Chem.* 257: 14256-14262) (Fig. 3C). In addition, it was specific for cholesterol since no uptake of other radiolabeled steroid could be seen (Fig. 3D), and could not be saturated at the

concentrations of radiolabeled cholesterol used (Fig. 3E), suggesting that PBR functions as a channel for cholesterol rather than a cholesterol-binding protein, which is in agreement with the modeling studies (Bernassau, et al., 1993, *supra*; Papadopoulos, V. 1996, *supra*). When IPTG-induced, cholesterol-loaded, bacterial membranes were treated with PK 11195, cholesterol was liberated from the membranes (Fig. 3F), suggesting that cholesterol captured by PBR is released upon ligand binding. Thus, PBR serves a channel-like or a port function where cholesterol can enter and reside stored within the membrane without interacting with the lipid or protein components of the lipid bilayer. This may also be the way by which the mitochondria sort between the steroidogenic pool of cholesterol from the cholesterol component of the membrane. Thus, PBR ligands control the opening/release state of the channel, mediating cholesterol movement across membranes. In addition to the PBR drug ligands, the polypeptide diazepam binding inhibitor (DBI) and porphyrins (Papadopoulos, V. 1993, *supra*) have been identified as naturally occurring endogenous ligands. It should be noted that at present we couldn't exclude the possibility that PBR functions as a flippase or a transporter.

In support of the data presented herein, targeted disruption of the PBR gene in steroidogenic cells resulted in inhibition of cholesterol transport to IMM and arrest of steroid biosynthesis (Papadopoulos, V. et al. 1997, *J. Biol. Chem.* 272:32129-32135). Transfecting PBR mutant Leydig cells with the PBR cDNA rescued steroidogenesis and demonstrated the obligatory role of PBR in cholesterol transport (Papadopoulos, V. 1996, *supra*).

Example 2

PBR is an 18 kDa hydrophobic protein with five putative transmembrane domains located in the OMM. As a first step in defining the regions of the receptor involved in the interaction with the drug ligand and cholesterol, we constructed mutant PBRs with the deletions indicated in the left panel of Fig. 4. The location of the five transmembrane regions of the receptor (I to V) is also shown in Fig. 4. It should be noted that the amino-terminus of mitochondrial membrane proteins is directed towards the inside of the organelle whereas the carboxy-terminus is in the cytoplasmic side. The right panel of Fig. 4 shows the effect of deletion of specific amino acid sequences on PBR ligand binding and cholesterol uptake examined in the bacterial system described above. Deletion of amino acid sequences 5-20 and 41-51 in the amino-terminus of the receptor decreased by 30-45% the ability of PBR to bind the ligand PK 11195. Our results are in agreement with previous studies on human PBR expressed in yeast (Farges, R. et al., 1994, *Mol. Pharm.* 46:1160-1167), although in those studies deletion of the amino-terminus of human PBR completely abolished the ability of the receptor to bind PK 11195. Deletion of amino acids 120-133 in the fourth transmembrane domain also decreased PBR ligand binding by 45%. Smaller decrease (25%) of PK 11195 binding was also seen when the regions 141-152 and 153-169 were deleted. These results suggest that although the amino-terminus of the receptor may confer the ability to bind drug ligands, such as the isoquinoline PK 11195, amino acid sequences in the fourth transmembrane domain may participate in the formation of the ligand binding site. It should be noted that

deletions affecting PK 11195 ligand binding did not had a major effect on the ability of the recombinant receptor expressed in bacterial membranes to take up radiolabeled cholesterol.

5 Fig. 4 also shows that deletion of amino acids 153-169 in the carboxy-terminus of PBR had a dramatic effect on the ability of the molecule to take up ^3H -cholesterol when expressed in bacteria (70% decrease). This result suggests that the cytoplasmic carboxy-
10 terminal domain of the receptor is responsible for the interaction and subsequent uptake of cholesterol. In an effort to identify specific amino acids in PBR responsible for the interaction with cholesterol we undertook site-directed mutagenesis studies in the
15 carboxy-terminal region.

Example 3

Recent studies by Pikuleva *et al.* (1995, *Arch. Biochem. Biophys.* 322:189-197) with another protein
20 that interacts with cholesterol, the enzyme P450scc, indicated that a Tyrosine in the active site of the P450scc interacts with the side chain of cholesterol. Aligning the P450scc active site amino acid sequence with the carboxy-terminus of PBR indicated that there
25 might be a common amino acid consensus pattern in these two molecules recognizing cholesterol (Table I). This consensus pattern is composed of a neutral and hydrophobic amino acid (Z), such as Leucine or Valine, a neutral and polar amino acid (Y), such as Tyrosine,
30 and a basic amino acid (Q), such as Arginine or Lysine. One to five different amino acids may be placed between these three coding amino acids. Thus, the proposed consensus pattern is $-\text{Z}-(\text{X})_{0-5}-\text{Y}-(\text{X})_{0-5}-\text{Q}-$. Leucine or Valine will interact with the
35 hydrophobic side chain of cholesterol and Tyrosine

will interact with the polar 3'OH-group of cholesterol, whereas the Arginine or Lysine may help create a pocket. This hypothesis was tested (Fig. 5). Replacement of Y153 by Serine or R156 by Leucine
5 completely abolished the ability of PBR to take up radiolabeled cholesterol. Mutation and replacement of A147 with Threonine, did not affect cholesterol uptake by bacteria expressing the mutated receptor. Fig. 5
10 also shows that the wild-type and mutated recombinant receptor proteins were expressed at equal levels upon IPTG induction.

Example 4

In an effort to see whether this putative
15 cholesterol recognition/interaction amino acid consensus pattern is present in other molecules shown or suggested to interact with cholesterol, such as the as apolipoprotein A-1 (Boyle, T. P. and Marotti, K.R., 1992, *Gene* 117, 243-247), caveolin (Murata, M. et al.
20 1995, *Proc. Natl. Aca. Sci. USA* 92, 10339-10343), DBI (Papadopoulos, V. 1993, *Endocr. Rev.* 14, 222-240; Papadopoulos, V. 1998, *Proc. Soc. Exp. Biol. Med.* 217, 130-142), steroidogenesis acute regulatory protein (StAR) (Stocco, D. M. and Clark, B. J. 1996, *Endocr.*
25 *Rev.* 17, 221-244), hedgehog protein (Porter, J. A. et al. 1996, *Science* 274, 255-259), cytochrome P450 C26/25 (Su, P. et al. 1990, *DNA Cell Biol.* 9-657-667), annexin II (Harder, T. et al. 1997, *Mol. Biol. Cell* 8, 533-545), sterol carrier protein-2 (Colles, S. M. et
30 al. 1995, *Lipids* 30, 795-803), cholesterol 7 α -monooxygenase (Kai, M. et al. 1995, *Lipid Res.* 36, 367-374), cholesterol oxidase (Ishizaki, T. et al. 1991, *J. Bacteriol.* 171, 596-601), cholesterol dehydrogenase (Horinouchi, S. et al. 1991, *Appl.*
35 *Environ. Microbiol.* 57, 1386-1393), bile-salt-

activated lipase precursor (cholesterol esterase)
 (Nilsson, J. et al. 1990, *Eur. J. Biochem.* 192, 543-
 550), and acyl-CoA cholesterol acyltransferase (Pape,
 M.E. et al. 1995, *J. Lipid Res.* 36, 823-838) we looked
 5 for the presence of the cholesterol
 recognition/interaction amino acid consensus pattern -
Z-(X)₀₋₅-Y-(X)₀₋₅-Q- in these proteins. Table I shows
 that all these proteins, with the exception of sterol
 carrier protein-2, contain this amino acid consensus
 10 pattern. Proteins such as rat skeletal muscle alpha-
 actin, non-muscle and smooth muscle myosin light chain
 did not contain this cholesterol
 recognition/interaction consensus pattern. However,
 given any tyrosine there is a reasonably high
 15 probability that this consensus amino acid sequence
 will be found in many proteins. Indeed, a motif
 search through the various gene data banks indicated
 that this amino acid consensus pattern is present in
 various proteins. This is not surprising since it is
 20 known that the cholesterol/protein interaction plays a
 role not only in cholesterol transport and/or storage
 but also in protein stability, folding, and/or
 localization. Thus, it is possible that only in some
 proteins this consensus sequence will be functional.
 25 The strength and specificity of the interaction of a
 protein containing this consensus amino acid sequence
 with cholesterol may be due either to the presence of
 a certain microenvironment, or the location of the
 consensus sequence within the protein, or a specific
 30 conformation of the protein that allows the use of
 this amino acid sequence. In the latter case, it is
 also possible that the consensus sequence identified
 represents only a portion, maybe the core, of a larger
 motif to be identified.

Of special interest to steroidogenesis is the observation that the cholesterol recognition/interaction amino acid consensus pattern was found in the polypeptide DBI (Papadopoulos, V. 1993, *supra*; Papadopoulos, V. 1998, *supra*) and the precursor StAR protein (Stocco, D. M. and Clark, B. J. 1996, *Endocr. Rev.* 17, 221-244). In search of a cytosolic steroidogenesis-stimulating factor, a protein was purified shown to be identical to DBI (Papadopoulos, V. 1993, *supra*). DBI was originally purified from brain by monitoring its ability to displace diazepam from its recognition sites in synaptosomes. DBI is also identical to the acyl-CoA-binding protein (Knudsen, J. *et al.*, 1993, *Mol. Cell. Biochem.* 123:129-138). Purified DBI was shown to stimulate intramitochondrial cholesterol transport and increase pregnenolone formation by isolated mitochondria (Papadopoulos, V., 1998, *supra*). Later on, it was demonstrated that this action of DBI was mediated by PBR (Papadopoulos, V. 1993, *supra*; Papadopoulos, V. 1998, *supra*). In addition DBI was shown to increase cholesterol loading onto isolated P450_{scc} (Brown, A. S. and Hall, P. F., 1991 *Biochem. Biophys. Res. Commun.* 180:609-614). Thus, the identification of the cholesterol recognition/interaction amino acid consensus pattern in DBI may help understand its role in steroidogenesis and its direct effect on P450_{scc}. Interestingly, we showed in the past that the naturally occurring processing product of DBI, the triakontatetrapeptide TTN (DBI₁₇₋₅₀), but not the octadecaneuropeptide ODN (DBI₃₃₋₅₀), was able to mimic the effect of DBI on mitochondrial steroidogenesis (Papadopoulos, V. *et al.* 1991, *Endocrinology* 129:1481-1488). The finding that in DBI the cholesterol recognition/interaction amino

acid consensus pattern is located in the amino acid
sequence 25 to 32 (Table I) may now explain this
result. It should be also noted that the cholesterol
recognition/interaction amino acid consensus pattern
5 is found in the middle of the acyl-CoA-binding protein
signature domain (amino acids 19 to 37) important in
forming the acyl-CoA-binding site (Knudsen et al.
1993, *supra*).

STAR has been found in gonadal and adrenal cells,
10 where it is newly synthesized in response to trophic
hormones, as a cytoplasmic precursor protein of 37 kDa
targeted to mitochondria (Stocco and Clark, 1996
supra). STAR synthesis in Leydig cells begins 60 min
after addition of the hormone and then parallels the
15 capacity of the cells to produce steroids in response
to tropic hormones (Stocco and Clark, 1996 *supra*;
Clark, B. J. et al., 1995, *Mol. Endocr.* 9:1346-1355).
The 37 kDa STAR precursor further undergoes cleavage
to produce the 30 kDa mitochondrial "mature" STAR
20 protein and its phosphorylated counterpart (Stocco and
Clark, 1996 *supra*). This protein processing is
believed to occur at the level of the outer/inner
mitochondrial membrane contact sites and it has been
proposed to be responsible for cholesterol transport
25 from outer to inner mitochondrial membrane (Stocco and
Clark, 1996 *supra*). Considering that the cholesterol
recognition/interaction amino acid consensus pattern
is found in the amino-terminus of the STAR precursor
protein, which is removed from the mature protein, it
30 is possible that the function of the precursor STAR
protein is to shuttle cholesterol from intracellular
stores to the outer mitochondrial membrane.

In conclusion, the results presented herein
demonstrate that PBR may have a channel-like function
35 for cholesterol in the OMM. The steroidogenic pool of

cholesterol, coming from various intracellular sources, is recognized by the cholesterol recognition/interaction amino acid consensus pattern - **Z-(X)₀₋₅-Y-(X)₀₋₅-Q-** present in the carboxy-terminus of PBR in the OMM. This pool of cholesterol enters in the OMM at the PBR sites where it remains without mixing with other membrane components. Ligand binding to the receptor induces the release of this cholesterol. Considering that PBR has been shown to be associated with the voltage-dependent anion channel (Papadopoulos, V. 1998, *supra*), found in the outer/inner mitochondrial membrane contact sites, the released cholesterol could now directly access the P450scc in the IMM where it will be cleaved to pregnenolone, precursor of all steroids.

In addition to being a precursor for steroid hormone synthesis, cholesterol is an essential structural element of cellular membranes and a precursor for the synthesis of bile acids and lipoproteins. Mammalian cells obtain cholesterol by internalization of low-density lipoproteins or by *de novo* synthesis in the endoplasmic reticulum. The subcellular distribution of cholesterol suggests that cholesterol is trafficked and incorporated quickly from the sites of acquisition to the target membrane (Liscum, L and Underwood, K. W. 1995, *J. Biol. Chem.* 270:15433-15446). Thus, a tissue and cell specific cholesterol homeostasis is achieved. Considering the widespread occurrence of PBR and its tissue and cell specific subcellular localization (Papadopoulos, V. 1993, *supra*; Papadopoulos, V. 1998, *supra*), these results suggest a more general role for PBR in intracellular cholesterol transport and compartmentalization.

What is claimed is:

1. A cholesterol recognition/interaction amino acid consensus sequence comprising

5 $Z-(X)_{0-5}-Y-(X)_{0-5}-Q$

wherein Z is a neutral hydrophobic amino acid, Y is a neutral polar amino acid, Q is a basic amino acid and X is any amino acid.

10 2. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein Z is Leucine or Valine.

15 3. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein Y is Tyrosine.

20 4. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein Q is Arginine or Lysine.

25 5. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein
 (i) Z is leucine or Valine;
 (ii) Q is Arginine or Lysine; and
 (iii) Y is Tyrosine.

30 6. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein X is one amino acid.

7. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein X is two amino acids.

8. The cholesterol recognition/interaction amino acid consensus sequence of claim 1 wherein X is 1-3 amino acids.

5

9. A nucleic acid molecule encoding the consensus sequence of claim 1.

10. A nucleic acid molecule comprising:

10

(i) a vector; and

(ii) the nucleic acid molecule of comprising a cholesterol interaction/recognition consensus of claim 9.

15

11. The nucleic acid molecule according to claim 10 wherein said vector is a prokaryotic vector.

12. The nucleic acid molecule according to claim 11 wherein said vector is an expression vector.

20

13. The nucleic acid molecule according to claim 10 wherein said vector is a eukaryotic vector.

14. The nucleic acid molecule according to claim 13 wherein said vector is an expression vector.

15. The nucleic acid molecule according to claim 13 wherein said vector is useful for expression in plants.

30

16. A host cell transformed with the nucleic acid molecule of claim 10.

17. The host cell of claim 16 wherein said host cell is prokaryotic.

35

18. The host cell of claim 16 wherein said host cell is eukaryotic.

5 19. The host cell of claim 16 wherein said host is a plant cell.

20. A peptide comprising a cholesterol interaction/recognition sequence according to claim 1.
10

21. A method for detecting whether or not a protein recognizes cholesterol comprising identifying in the amino acid sequence or the nucleic acid sequence of said protein the presence or absence of a
15 cholesterol recognition/interaction consensus sequence according to claim 1 wherein the presence of the consensus sequence indicates possible interaction/recognition of the protein with cholesterol.

20
22. A method for conferring cholesterol recognition/interaction to a molecule comprising introducing into said molecule a cholesterol recognition/interaction sequence according to claim 1
25 such that said sequence is expressed and said molecule interacts with cholesterol.

23. A method for reducing serum cholesterol in a subject, said method comprising introducing into said
30 subject a nucleic acid comprising the cholesterol interaction/recognition consensus sequence according to claim 1 such that it is expressed and is able to interact with cholesterol.

24. A method for delivering cholesterol to a subject comprising administering a peptide comprising the cholesterol interaction/recognition consensus sequence according to claim 1 complexed with
5 cholesterol in a pharmaceutically acceptable amount, in a pharmaceutically acceptable diluent.

25. A method for detecting an increase or decrease of cholesterol in a biological sample
10 comprising
immobilizing a polypeptide comprising the cholesterol interaction/recognition consensus sequence according to claim 1 on a solid support rendering an immobilized polypeptide,
15 exposing the sample to the immobilized polypeptide, and
measuring the amount of cholesterol-bound polypeptide wherein when comparing to a standard, an increase or decrease over the standard can be
20 determined.

26. A method for screening agents or drugs which are agonists or antagonist of interaction between peptides comprising the cholesterol recognition/
25 interaction consensus sequence according to claim 1 and cholesterol comprising
exposing a polypeptide comprising the consensus sequence of the present invention to cholesterol under conditions where interaction between cholesterol and
30 the peptide occurs forming a peptide/cholesterol complex
incubating the complex with a test compound
measuring an increase or decrease in the level of interaction between the polypeptide and cholesterol in
35 response to the test compound where an increase in

interaction would indicate that the test compound is an agonist and a decrease in interaction would indicate that the test compound is an antagonist of peptide/cholesterol binding.

5

27. A molecule which blocks cholesterol interaction with the cholesterol recognition/interaction consensus sequence according to claim 1.

10

28. The molecule according to claim 27 wherein said molecule is selected from the group consisting of: a peptide, a drug, and an antibody.

15

29. A method for reducing the cholesterol binding ability of peptide which comprise the cholesterol recognition/interaction consensus sequence according to claim 1 comprising

20

modifying Y from a tyrosine to a serine, or
modifying Q from an arginine to a leucine.

25

30. A peripheral-type benzodiazepine receptor wherein the cholesterol recognition/interaction function of said receptor is reduced according to the method of claim 29.

30

31. A peripheral-type benzodiazepine receptor unable to recognize/interact with cholesterol said receptor comprising a deletion comprising a cholesterol interaction/recognition sequence of said receptor.

35

31. A method for reducing disease symptoms in a subject resulting from an increase in cholesterol, said method comprising administering to said subject a

nucleic acid encoding a peptide comprising a
cholesterol recognition/interaction consensus sequence
such that said nucleic acid is expressed and said
peptide is produced in a therapeutically effective
5 amount.

32. The method of claim 31 wherein said
administration is by microspheres.

10 33. A transgenic plant comprising a nucleic acid
encoding a peripheral-type benzodiazepine receptor
according to claim 30.

15 34. A transgenic plant comprising a nucleic acid
encoding a peripheral-type benzodiazepine receptor
according to claim 31.

20 35. A transgenic plant comprising a nucleic acid
encoding a peripheral-type benzodiazepine receptor
operably linked to an inducible promoter.

25 36. The transgenic plant according to claim 35
wherein said promoter is inducible any of the
following conditions: heat, administration of
antibiotic, administration of plant hormone.

30




FIGURE 1



FIG 2A




Fig 2B




FIGURE 2C




FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 3D




FIGURE 3E





FIGURE 3F

1A

09/623922

Deletion of PBR



09/623922 4




FIGURE 5

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED

the specification of which (CHECK applicable BOX(ES))

X ☐ is attached hereto.
BOX(ES) → B. ☐ was filed on _____ as U.S. Application No. _____ /
→ C. ☒ was filed as PCT International Application No. PCT/ US99/05853 on March 12, 1999

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S)

Number	Country	Day/MONTH/Year Filed	Date first Laid-open or Published	Date Patented or Granted	Priority NOT Claimed
PCT/US99/05853	International	12 March 1999			

If more than one foreign applications, X box at bottom and continue on attached page.

As noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)

Application No. (series code/serial no.)	Day/MONTH/Year Filed	Status	Priority NOT Claimed
60/077,753	12 March 1998	pending, abandoned, patented	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop LLP, Intellectual Property Group, telephone number (703) 905-2000 (to whom all communications are to be directed), and persons of that firm who are associated with USPTO Customer No. 909 (see below label) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete from that Customer No. names of persons no longer with their firm, to add new persons of their firm to that Customer No., and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or an attorney of that Firm in writing to the contrary

USE ONLY FOR
PILLSBURY WINTHROP



00909

(1) INVENTOR'S SIGNATURE:

Date: 8/16/01

Name	Vassilios	Papadopoulos
First	Middle Initial	Family Name
Residence	North Potomac	Maryland, U.S.A.
City	State/Foreign Country	Country of Citizenship
Mailing Address	15417 Peach Leaf Drive, North Potomac, Maryland	
(include Zip Code)		

(2) INVENTOR'S SIGNATURE:

Date: 8/20/01

Name	Hua	Li
First	Middle Initial	Family Name
Residence	Arlington	Virginia, U.S.A.
City	State/Foreign Country	Country of Citizenship
Mailing Address	1319 North Fort Myer Drive, Apt. 102, Arlington, Virginia	
(include Zip Code)		

☐ FOR ADDITIONAL INVENTORS see attached page.

☐ See additional foreign priorities on attached page (incorporated herein by reference).

Atty. Dkt. No. P23521-0159

(M#)

**VERIFIED STATEMENT BY A NON-INVENTOR SUPPORTING
A CLAIM BY ANOTHER FOR SMALL ENTITY STATUS**

Docket No.
23521.0159

Serial No.
New Application

Filing Date
September 11, 2000

Patent No.
-

Issue Date
-

Applicant/ **Vassilios Papadopoulos and Hua Li**
Patentee:

Invention: **CHOLESTEROL RECOGNITION SEQUENCE**

I hereby declare that I am making this verified statement to support a claim by
VASSILIOS PAPADOPOULOS AND HUA LI

for small entity status for purposes of paying reduced fees to the United States Patent and Trademark Office, regarding the invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

I hereby declare that I would qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying fees to the United States Patent and Trademark Office, if I had made the above identified invention.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). Note: Separate verified statements are required from each person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern, or organization exists.
☒ each such person, concern or organization is listed below.

FULL NAME **Georgetown University Medical Center**

ADDRESS **4000 Reservoir Road, N.W., Washington, D.C. 20007**

☐ Individual ☐ Small Business Concern ☒ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Robin L. Teskin

TITLE IN ORGANIZATION: _____

ADDRESS OF PERSON SIGNING: Shaw Pittman
2300 N Street, N.W.
Washington, D.C. 20037-1128

SIGNATURE: _____



DATE: SEPTEMBER 11, 2000

U.S. PATENT AND TRADEMARK OFFICE